Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Core Viewpoint - Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For Coya Therapeutics, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to a rise in stock price as investors respond positively to this trend [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Coya Therapeutics is expected to earn -$1.12 per share, which remains unchanged from the previous year. However, the Zacks Consensus Estimate has increased by 6.5% over the past three months, indicating a positive revision trend [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating. Coya Therapeutics' upgrade to Zacks Rank 2 places it in this top tier, suggesting potential for market-beating returns in the near term [9][10].